Monitoring acute and longer-term effects of cannabis on psychomotor performance in daily life in medical cannabis patients

监测大麻对医用大麻患者日常生活中精神运动表现的急性和长期影响

• 批准号: 10657179
• 负责人: Tammy Chung
• 金额: $ 76.26万
• 依托单位: RUTGERS BIOMEDICAL AND HEALTH SCIENCES
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-08-15 至 2028-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10657179
• 关键词: Accelerometer; Acute; Adverse effects; Age; Alcohols; Anxiety; Automobile Driving; Awareness; Cannabis; Cellular Phone; Cognitive; Collaborations; Data; Data Collection; Development; Digit structure; Drug usage; Ecological momentary assessment; Exclusion; Female; Frequencies; Goals; Grain; Impairment; Individual; Intervention; Intoxication; Life; Link; Measures; Mediating; Mediation; Medical; Medical Marijuana; Methods; Modeling; Monitor; National Institute of Drug Abuse; Outcome; Pain; Participant; Patient Self-Report; Patients; Performance at work; Persons; Pharmaceutical Preparations; Psychomotor Performance; Reaction; Reaction Time; Reporting; Risk; Risk Reduction; Speed; Substance Use Disorder; Symptoms; Telephone; Testing; Therapeutic; Therapeutic Effect; Therapeutic Uses; Time; Visit; alcohol and other drug; anxiety symptoms; chronic pain; cognitive function; computerized; design; driving skills; follow-up; gender difference; improved; interest; mHealth; marijuana use; marijuana use disorder; novel; pain symptom; recruit; response; saliva sample; salivary assay; self-reported anxiety; sensor; side effect

ABSTRACT Although therapeutic use of cannabis is increasing, findings are mixed regarding therapeutic effects of cannabis for certain conditions, such as anxiety. Further, acute cannabis effects could adversely impact psychomotor performance (e.g., slowed reaction time), with subsequent negative effects on daily activities (e.g., work performance, driving skills). Low burden methods to monitor acute cannabis effects through sensors in personal smartphones could ultimately help reduce cannabis's acute negative effects on psychomotor performance by helping to raise a person's awareness of cannabis-related impairment. Toward this goal, this R01 will collaborate with individuals who use medical cannabis (MC) in monitoring, with their smartphone, acute therapeutic and adverse effects of cannabis use. Individuals who use MC commonly report cannabis use to relieve chronic pain and/or anxiety, the two conditions of interest for this R01. Smartphone will be used to conduct symptom monitoring of acute cannabis effects on chronic pain and anxiety using Ecological Momentary Assessment (EMA). Phone sensor data will be used to examine acute cannabis effects on psychomotor performance. These fine-grained smartphone "micro" data (e.g., momentary-level) will be combined with longer-term follow-up over 1-year, to examine the impact of cannabis use at a more "macro" level (e.g., over months), because cannabis effects (e.g., on anxiety) at "micro" and "macro" time scales may differ. This R01 will recruit individuals who report therapeutic use of cannabis, with chronic pain and/or anxiety as the primary reasons for MC use (N=400, age >18; 50% female). Participants complete lab assessments at baseline, 3-, 6-, and 12-months in a repeated measures design. Saliva sample for THC and CBD level will be done at baseline, 3-, 6-, and 12-months. Each assessment (baseline, 3-, 6-, 12-months) is followed by 14-day daily EMA and phone sensor data collection. Daily EMA (3x/day) and self-initiated EMA of cannabis use (medical, non-medical) will be used. Phone sensor data include, for example, keyboard use (not message content), and accelerometer (e.g., to detect activity level). Study aim 1 will examine links between acute cannabis use and effects (EMA report), psychomotor performance (phone sensor data), and self-reported daily cognitive functioning (e.g., react slowly to things). Study aim 2 will test links, over 1-year, of longer-term effects of cannabis use, computerized measures of psychomotor performance, and self-report of cannabis-related consequences. For each aim, gender differences in cannabis's short and longer term effects will be explored. The combination of fine-grained subjective (EMA) and objective (phone sensor) data, collected at micro (EMA) and macro time scales over 1-year, will help resolve mixed findings on possible cannabis-related therapeutic benefit, acute risks, and longer-term outcomes (e.g., on psychomotor performance). In line with NIDA priorities, this R01's novel combination of symptom monitoring methods (EMA, phone sensor data), and "micro" and "macro" data, will guide development of mHealth interventions that reduce risk for cannabis-related harm.

摘要 尽管大麻的治疗用途正在增加，但关于大麻的治疗效果，研究结果好坏参半。 对于某些情况，如焦虑症，服用大麻。此外，大麻的急性影响可能产生不利影响。 精神运动表现(例如，反应时间减慢)，对日常活动产生负面影响 (例如，工作表现、驾驶技能)。通过以下途径监测急性大麻效应的低负担方法 个人智能手机中的传感器最终可能有助于减少大麻对 精神运动表现，帮助提高一个人对大麻相关损害的认识。冲向 为了实现这一目标，本R01将与使用医用大麻(MC)的个人合作监测，与他们的 智能手机、大麻使用的急性治疗和不良反应。经常使用MC的个人报告 大麻用于缓解慢性疼痛和/或焦虑，这是R01感兴趣的两个条件。智能手机将 用于急性大麻对慢性疼痛和焦虑的症状监测 瞬时评估(EMA)。手机传感器数据将被用来检查大麻对 精神运动表现。这些细粒度的智能手机“微”数据(例如，瞬时级别)将是 结合1年以上的长期跟踪，在更宏观的层面上审查大麻使用的影响 在“微观”和“宏观”时间尺度上，大麻的影响(例如，对焦虑的影响)可能 不同。R01将招募报告使用大麻治疗的有慢性疼痛和/或焦虑的个人 作为使用MC的主要原因(N=400，年龄&GT；18；50%女性)。参与者在以下位置完成实验室评估： 重复测量设计中的基线、3个月、6个月和12个月。THC和CBD水平的唾液样本将是 在基线、3个月、6个月和12个月时完成。每项评估(基准、3个月、6个月、12个月)之后是14天 日常EMA和电话传感器数据收集。每日EMA(3次/天)和自我发起的EMA吸食大麻 (医疗，非医疗)将被使用。电话传感器数据包括例如键盘使用(不是消息 内容)和加速计(例如，用于检测活动水平)。研究目标1将检查急性呼吸道感染之间的联系 大麻使用和影响(EMA报告)、精神运动表现(电话传感器数据)和每日自我报告 认知功能(例如，对事物反应迟缓)。研究目标2将在一年内测试长期影响的联系 大麻使用情况、精神运动表现的计算机化测量以及与大麻有关的自我报告 后果。对于每个目标，将探讨大麻短期和长期影响的性别差异。 细粒度主观(EMA)和客观(电话传感器)数据的组合，在微观(EMA)收集 和宏观时间尺度超过一年，将有助于解决关于可能与大麻相关的治疗的混合发现 收益、急性风险和长期结果(例如，对精神运动表现的影响)。根据NIDA的优先事项， 这款R01‘S新颖的症状监测方法组合(EMA、手机传感器数据)，与“微”和 “宏观”数据将指导mHealth干预措施的发展，以降低大麻相关伤害的风险。